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INTRODUCTION
This chapter makes treatment recommendations for patients
with biopsy-proven membranous nephropathy (MN) be-
lieved to be of unknown cause (IMN). The treatment of
secondary forms of MN will not be covered in this chapter,
except for MN associated with hepatitis B and C. The cost
implications for global application of this guideline are
addressed in Chapter 2.
7.1: Evaluation of MN
7.1.1: Perform appropriate investigations to exclude
secondary causes in all cases of biopsy-proven
MN. (Not Graded)
BACKGROUND
The diagnosis of MN is made on kidney biopsy. Diagnostic
features include capillary wall thickening, normal cellularity,
IgG and C3 along capillary walls on immunofluorescence,
and subepithelial deposits on electron microscopy. MN is
often seen in association with an underlying disorder
(secondary MN).191–193 Secondary MN is more common in
children (75%) than adults (25%) (Table 12). The diagnosis
of IMN is made by exclusion of secondary causes, using
history, physical exam, and apppropriate laboratory tests
(e.g., serology, imaging) and by careful examination of the
kidney biopsy by light, immunofluorescence, and electron
microscopy. In IMN, deposition of the IgG4 subclass of IgG
is dominant, whereas other IgG subclasses dominate in
secondary forms of MN.194,195 Distinguishing secondary MN
from IMN is very important, since the therapy in the former
must be directed at the underlying cause and some of the
treatments for IMN are potentially toxic both to the patient
and the kidney.
RATIONALE
MN is due to a clinically recognizable underlying disorder in
a variable percentage of cases, depending on age and
geography.191–193,196,197,199–202 The recognition of the under-
lying disorder responsible for MN has important implica-
tions for prognosis and therapy.
MN is typically a disease of adults (fewer than 3% of
cases are found in children). The frequency and etiology
of secondary causes varies in different geographic
areas191–193,196,197,199–203 (Table 12). IMN is often a ‘‘diagnosis
of exclusion’’. A recent study200 has shown that about 70–80%
of IMN patients exhibit circulating antibodies of IgG4
subtype against a conformation-dependent epitope in the
M-type phospholipase A2 receptor. Such autoantibodies
appear to be absent or very uncommon in patients with
secondary MN. If the absence of autoantibodies to phos-
pholipase A2 receptor in secondary MN is validated and a
sensitive and specific assay for autoantibodies becomes
available, it could become a valuable marker to positively
identify (‘‘rule in’’) IMN. The IgG4 subclass dominates in the
deposits of IMN, while IgG1, IgG2, and/or IgG3 dominate in
secondary forms of MN.194,195
The most important secondary causes include systemic
lupus (in younger women), chronic hepatitis B infection
(especially in East Asia196), drugs (such as nonsteroidal anti-
inflammatory agents, gold and mercury compounds) and
malignancy (especially in patients presenting over the age
of 65 years). Specific evaluations should exclude secondary
causes of MN before specific immunosuppressive therapy is
considered. Detailed morphological studies show mesangial
deposits by electron microscopy and prominent IgG1, 2, or
3 subclass deposits by immunofluorescence in secondary
MN. These features can be helpful in suspecting a secondary
form of MN (see also Table 13 for a detailed listing of causes
of MN).
RESEARCH RECOMMENDATIONS
K Studies are needed to validate the utility of antibody
against M-type phospholipase A2 receptor in terms of its
accuracy in separating primary from secondary MN.
K Studies are needed to determine the most cost-effective
panel of investigations for screening an underlying
(covert) malignancy in the older patient with MN.
7.2: Selection of adult patients with IMN to be considered
for treatment with immunosuppressive agents (see 7.8
for recommendations for children with IMN)
7.2.1: We recommend that initial therapy be started
only in patients with nephrotic syndrome
AND when at least one of the following
conditions is met:
K urinary protein excretion persistently ex-
ceeds 4 g/d AND remains at over 50% of the
baseline value, AND does not show pro-
gressive decline, during antihyper-
tensive and antiproteinuric therapy (see
Chapter 1) during an observation period
of at least 6 months; (1B)
K the presence of severe, disabling, or life-
threatening symptoms related to the ne-
phrotic syndrome; (1C)
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K SCr has risen by 30% or more within 6 to 12
months from the time of diagnosis but the
eGFR is not less than 25–30 ml/min per
1.73 m2 AND this change is not explained
by superimposed complications. (2C)
7.2.2: Do not use immunosuppressive therapy in
patients with a SCr persistently 43.5 mg/dl
(4309 lmol/l) (or an eGFR o30 ml/min per
1.73 m2) AND reduction of kidney size on
ultrasound (e.g., o8 cm in length) OR those
with concomitant severe or potentially life-
threatening infections. (Not Graded)
BACKGROUND
The commonest presentation of IMN is nephrotic syndrome
with preserved kidney function. About 50% of patients with
persistent high-grade proteinuria eventually progress to ESRD,
often after many years of observation. Complete remission of
nephrotic syndrome predicts excellent long-term kidney and
patient survival. A partial remission also significantly reduces
the risk of progression to ESRD (see Table 14 for definitions of
complete and partial remission used in this chapter). The
primary aims of treatment, therefore, are to induce a lasting
reduction in proteinuria. All currently used treatment
modalities have significant toxicity; therefore, selecting
patients at high risk of progression is important so that
exposure to treatment-related adverse events is minimized.
The degree and persistence of proteinuria during a period of
observation helps in selecting patients for this therapy. There is
no agreed definition of the ‘‘point of no return’’ in the
evolution of IMN after which the risks of immunosuppressive
drugs become unacceptable and futile. However, the presence
of severe tubular interstitial fibrosis, tubular atrophy, and
glomerular obsolescence on biopsy, accompanied by persistent
elevation of SCr 43.5mg/dl (4309mmol/l) (or eGFR
o30ml/min per 1.73m2), and reduction in kidney size on
ultrasound may be such indicators.
RATIONALE
K There is low- to moderate-quality evidence to support
a recommendation that patients with time-averaged
proteinuria o4.0 g/d or those who achieve a complete
or partial remission have an excellent long-term
prognosis.
K Observational studies of the natural history of IMN have
shown that male gender, persistent heavy proteinuria,
and elevated SCr at diagnosis predict the risk of later
progressive decline in kidney function, although these
factors may not all be independent risks.
K About 30–35% of patients with IMN eventually undergo
spontaneous remission of nephrotic syndrome; therefore,
it is reasonable to delay specific therapy for at least
6 months utilizing supportive therapy, including RAS
blockade (see Chapter 1 for details) unless the patient has
unexplained rapid deterioration in kidney function or
there are complications related to uncontrolled nephrotic
syndrome. However, the frequency of spontaneous
remissions is lower with higher grades of proteinuria at
presentation.
K It may be difficult to define precisely the time of onset of
a partial remission, since some patients experience a slow
reduction in proteinuria, even in the absence of specific
treatment, to non-nephrotic levels over several years.
K There is support for the use of predictive models for
determining risk of progression in IMN (i.e., persistent
proteinuria 44 g/d and/or decline in kidney function
over a 6-month period of observation).
K There is low-quality evidence to support a recommenda-
tion that the period of observation may be extended in
patients who exhibit a consistent progressive decline in
proteinuria during observation, have stable kidney
function, and no complications related to the nephrotic
state.
About 80% of adults with IMN have nephrotic syndrome
at presentation206 and the remainder have subnephrotic
proteinuria (see definitions in Chapter 1). The disease course
may be punctuated with spontaneous remissions and
relapses.197,207–214 In about 20% of patients, there is
spontaneous complete remission of the nephrotic syndrome,
and another 15–20% undergo partial remission. Remission
may be delayed for as long as 18–24 months. In a recent
Table 12 | Reported causes of secondary MN (% in adults)
China Japan France Finland United States
Cause
Zeng et al.196
(n=390)
Abe et al.191
(n=137)
Cahen et al.192
(n=82)
Honkanen197
(n=82)
Ehrenreich et al.198
(n=167)
IMN 31.8 65.0 79.3 69.8 62.3
Secondary MN 68.2 35.0 20.7 30.2 37.7
Autoimmune diseases 50.0 25.5 6.1 17.7 7.2
Infections 12.0 5.1 2.5 2.4
Tumors 3.1 1.5 4.9 2.1 1.8
Drugs or toxins 3.1 2.2 6.1 10.4 4.2
IMN, idiopathic membranous nephropathy; MN, membranous nephropathy.
Abe et al., Cahen et al., and Ehrenreich et al. also reported diabetes as a secondary cause of MN, accounting for 0.7%, 1.2%, and 16.8% of secondary MN cases, respectively.
Reprinted from Zeng CH, Chen HM, Wang RS et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis 2008; 52: 691–698
with permission from National Kidney Foundation;196 accessed http://www.ajkd.org/article/S0272-6386(08)01058-5/fulltext.
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study, the mean time to remission was 14.7±11.4 months
following presentation.215 About 15–30% suffer one or more
relapses, leaving about 50% of the patients with persistent
nephrotic syndrome. Data from natural history studies and
placebo arms of intervention studies show that about 30–40%
of the patients with persistent nephrotic syndrome progress
to ESRD over 10 years.208,216 Those with a persistent
nephrotic syndrome are also exposed to the related
complications, including infections, thromboembolic events,
and accelerated atherosclerotic cardiovascular disease.
The likelihood of spontaneous remission and progression
is dependent upon the age, gender, degree of proteinuria, and
kidney function at presentation.216,217 The risk of progression
is highest in those with proteinuria 48 g/d, persistent for
6 months. A validated algorithm allowed creation of a model
based on time-averaged proteinuria over 6 months, CrCl at
diagnosis, and the slope of CrCl over 6 months that correctly
identified patients at risk of progression with 85–90%
accuracy.218 Based on this model, patients at low risk for
progression present with a normal CrCl, proteinuria
consistently o4 g/d, and have stable kidney function over a
6-month observation period. Patients at medium risk for
progression (B50–55% probability of developing progressive
CKD over 10 years) have normal kidney function that
remains unchanged during 6 months of observation, but
continue to have proteinuria between 4 and 8 g/d. Those
classified as high risk for progression (65–80% probability of
progression to advanced CKD within 10 years from
diagnosis) have persistent proteinuria 48 g/d, independent
of the degree of kidney dysfunction.219,220 Treatment-induced
remissions are associated with an improved prognosis.221,222
The 10-year survival free of kidney failure is about 100% in
complete remission, 90% in partial remission, and 50% with
no remission. Patients with complete or partial remission
have a similar rate of decline in CrCl: 1.5ml/min/y for
complete remission, and 2ml/min/y for partial remission.
Although spontaneous remissions are less common in those
with higher baseline proteinuria, they are not unknown; a
recent report215 showed spontaneous remission in 26%
among those with baseline proteinuria 8–12 g/d and 22%
among those with proteinuria 412 g/d. Treatment with RAS
blockade, and a 50% decline of proteinuria from baseline
during the first year of follow-up, were significant indepen-
dent predictors for remission. Most reported natural history
studies were performed in an era before drugs that act on the
RAS became available. The long-term value of RAS blockade
in management of IMN has been assessed largely by
observational studies and has been observed only in those
patients with proteinuria (o10 g/d) at baseline. A recent
small RCT (n¼ 27) compared an ACE-I (lisinopril, up to
10mg/d) to an ARB (losartan, up to 100mg/d) in patients
with IMN and variable-range proteinuria (2.5–7 g/d). Both
agents were of comparable efficacy, reducing proteinuria on
average by 2.5 g/d by 12 months. The absence of a placebo
control and the failure to include patents with higher-grade
Table 13 | Reported causes of secondary MN
Autoimmune Infections
Autoimmune diseases Hepatitis B
Systemic lupus erythematosus Hepatitis C
Rheumatoid arthritis Human immunodeficiency virus
Mixed connective tissue disease Malaria
Dermatomyositis Schistosomiasis
Ankylosing spondylitis Filariasis
Systemic sclerosis Syphilis
Myasthenia gravis Enterococcal endocarditis
Bullous pemphigoid Hydatid disease
Autoimmune thyroid disease Leprosy
Sjo¨gren’s syndrome
Temporal arteritis
Crohn’s disease
Graft-versus-host disease
Malignancies
Carcinomas Noncarcinomas
Lung Hodgkin’s lymphoma
Esophageal Non-Hodgkin’s lymphoma
Colon Leukemia (chronic lymphocytic
leukemia)Breast
MesotheliomaStomach
MelanomaRenal
Wilm’s tumorOvary
Hepatic adenomaProstate
Angiolymphatic hyperplasiaOropharynx
Schwannoma
Neuroblastoma
Adrenal ganglioneuroma
Drugs/Toxins Miscellaneous
Gold Diabetes mellitus (association or
cause?)Penicillamine
SarcoidosisBucillamine
Sickle cell diseaseMercury compounds
Polycystic kidney diseaseCaptopril
a1-antitrypsin deficiencyProbenicid
Weber-Christian diseaseTrimethadione
Primary biliary cirrhosisNonsteroidal anti-inflammatory
drugs Systemic mastocytosis
Cyclooxygenase-2 inhibitors Guillain-Barre syndrome
Clopidogrel Urticarial vasculitis
Lithium Hemolytic-uremic syndrome
Formaldehyde Dermatitis herpetiformis
Hydrocarbons Myelodysplasia
Table 14 |Definitions of complete and partial remission
in IMN
Complete Remission: Urinary protein excretiono0.3 g/d (uPCRo300mg/
g or o30mg/mmol), confirmed by two values at least 1 week apart,
accompanied by a normal serum albumin concentration, and a
normal SCr.
Partial Remission: Urinary protein excretiono3.5 g/d (uPCRo3500mg/g
or o350mg/mmol) and a 50% or greater reduction from peak values;
confirmed by two values at least 1 week apart, accompanied by an
improvement or normalization of the serum albumin concentration
and stable SCr.
MN, membranous nephropathy; uPCR, urine protein:creatinine ratio.
See also Chapter 1.
Based on previously published information, Jha et al. and Passerini et al.204,205
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proteinuria (48–10 g/d) weaken the impact of the study.223
There is only low-quality evidence to support the value of
other predictors, such as hypertension, histologic evidence of
interstitial fibrosis and tubular atrophy, persistently elevated
urinary C5b-9, and excretion of increased quantities of low-
or high-molecular-weight proteins (b2-microglobulin and
IgG) in urine.224,225 Staging of MN by histologic criteria has
limited utility for prediction of outcomes or response to
therapy in IMN.
7.3: Initial therapy of IMN
7.3.1: We recommend that initial therapy consist of a
6-month course of alternating monthly cycles
of oral and i.v. corticosteroids, and oral
alkylating agents (see Table 15). (1B)
7.3.2: We suggest using cyclophosphamide rather
than chlorambucil for initial therapy. (2B)
7.3.3: We recommend patients be managed conser-
vatively for at least 6 months following the
completion of this regimen before being
considered a treatment failure if there is no
remission, unless kidney function is deterior-
ating or severe, disabling, or potentially life-
threatening symptoms related to the nephrotic
syndrome are present (see also Recommenda-
tion 7.2.1). (1C)
7.3.4: Perform a repeat kidney biopsy only if the
patient has rapidly deteriorating kidney func-
tion (doubling of SCr over 1–2 month of
observation), in the absence of massive
proteinuria (415 g/d). (Not Graded)
7.3.5: Adjust the dose of cyclophosphamide or
chlorambucil according to the age of the
patient and eGFR. (Not Graded)
7.3.6: We suggest that continuous daily (noncyclical)
use of oral alkylating agents may also be
effective, but can be associated with greater
risk of toxicity, particularly when adminis-
tered for 46 months. (2C)
BACKGROUND
Three RCTs have shown that monotherapy with oral
corticosteroids is not superior to symptomatic therapy alone
in IMN. Orally administered akylating agents (cyclophos-
phamide or chlorambucil), most commonly in conjunction
with steroids, are effective in inducing remission and
preventing ESRD (Online Suppl Tables 22–25). The toxicity
profile suggests that cyclophosphamide might be preferred to
chlorambucil.
RATIONALE
K There is moderate-quality evidence to recommend a
6-month cyclical regimen of alternating alkylating agents
(cyclophosphamide or chlorambucil) plus i.v. pulse and
oral corticosteroids (see Table 15 for description of
regimen) for initial therapy of IMN meeting the criteria
in Recommendation 7.2.1 above. This evidence indicates
this treatment is superior to supportive therapy alone
in inducing remissions and preventing long-term
decline of kidney function, including the need for
dialysis, in patients with IMN and persisting nephrotic
syndrome. The risks and adverse events associated with
the use of cyclophosphamide in IMN are summarized in
Table 16.
K Other combined regimens of cyclophosphamide and
corticosteroids have also been used. Some omit i.v.
methylprednisolone, others use alkylating agent and
corticosteroids concurrently, rather than cyclically, for a
longer duration.226–228 However, the long-term efficacy
and safety of these regimens are less well-established than
the cyclical regimen.229 The safety and efficacy of i.v.
cyclophosphamide-based regimens for treatment of IMN
have not been sufficiently evaluated to warrant any
recommendations. One small (underpowered) controlled
trial in progressive IMN was negative.230 The evidence is
insufficient to make any recommendations regarding the
use of i.v. compared to oral cyclophosphamide.
K A complete or partial remission of nephrotic syndrome is
associated with an excellent long-term prognosis; there-
fore, persisting remission of the nephrotic state is an
acceptable surrogate end-point to assess overall efficacy of
treatment.
K Treated patients may continue to enter complete or
partial remission for as long as 12–18 months following
completion of the regimen, so it is reasonable to wait this
period of time before deciding whether the initial
treatment has been unsuccessful (see Recommendations
7.6.1 and 7.6.2), providing that serum albumin levels or
kidney function are not deteriorating, and that morbid
events have not supervened. During the period of
observation, patients should continue to receive ACE-I
or ARBs, other antihypertensives, and other supportive
therapies as clinically indicated. In comparative studies,
cyclophosphamide has a superior safety profile compared
to chlorambucil. There is low-quality evidence that
cyclophosphamide can lead to more frequent and longer
remissions than chlorambucil. Cumulative toxicities of
Table 15 | Cyclical corticosteroid/alkylating-agent therapy
for IMN (the ‘‘Ponticelli Regimen’’)
Month 1: i.v. methylprednisolone (1 g) daily for three doses, then oral
methyprednisolone (0.5mg/kg/d) for 27 days
Month 2: Oral chlorambucil (0.15–0.2mg/kg/d) or oral cyclophosphamide
(2.0mg/kg/d) for 30 daysa
Month 3: Repeat Month 1
Month 4: Repeat Month 2
Month 5: Repeat Month 1
Month 6: Repeat Month 2
IMN, idiopathic membranous nephropathy.
aMonitor every 2 weeks for 2 months, then every month for 6 months, with serum
creatinine, urinary protein excretion, serum albumin, and white blood cell count. If
total leukocyte count falls to o3500/mm3, then hold chlorambucil or cyclophos-
phamide until recovery to 44000/mm3.
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alkylating agents can be significant and require careful
monitoring by the treating physician. A recent study of
the use of cyclophosphamide- or chlorambucil-based
regimens in IMN has raised concerns regarding safety,
given a reported adverse-event rate that exceeded 80%.231
This is in contrast to the older long-term RCT of cyclical
alkylating agents and steroids, where the regimens were
well-tolerated with an acceptably low frequency of serious
adverse events.229,232,233 Risks of this regimen are now
known to be increased if alkylating agents are used in
patients with reduced renal function, older age, and/or
concomitant comorbidities as evidenced in this recent
report.
K Since the decline in GFR in IMN is often very gradual,
especially in the absence of massive proteinuria, any
acceleration of the rate of decline indicates the possibility
of a superimposed disease process (such as crescentic
glomerulonephritis or acute interstitial nephritis, which
is often drug-related) that might dictate a change in
treatment approach. A repeat kidney biopsy is necessary
to identify these conditions.
K Relapses of nephrotic syndrome occur in about 25%
of patients treated with the ‘‘Ponticelli’’ regimen. A
similar fraction of patients with spontaneous remissions
also will relapse (see treatment of relapses in IMN in
Section 7.7).
An open-label RCT utilizing a 6-month course of
chlorambucil and steroids in alternating monthly cycles was
initiated in the 1980s (see Table 15 for the description of the
regimen).229,232,233 After 10 years of follow-up, 92% of the
treated (n¼ 42) and 60% of the control (n¼ 39) patients
were alive with normal kidney function (P¼ 0.0038). There
was remission in 61% (40% complete remission) and 33%
(5% complete remission) in the two groups. In another
RCT,234 this same regimen was compared to one where
steroids alone were used for the entire 6-month period
(chlorambucil was substituted with oral prednisolone 0.5mg/
kg/d). A significantly higher proportion of patients in the
chlorambucil arm were in remission in the first 3 years. The
difference was lost at 4 years, probably because of a small
number of at-risk cases. The duration of remission was also
longer in those treated with chlorambucil. Another RCT235
compared the same combination of chlorambucil and
steroids to one in which chlorambucil had been replaced
with oral cyclophosphamide (2.5mg/kg/d). Remission of
nephrotic syndrome was noted with equal frequency in
the two arms (82% vs. 93%; P¼ 0.116) (Online Suppl
Tables 22–25). However, severe adverse effects leading to
discontinuation of therapy occurred more frequently in the
chlorambucil group compared to the cyclophosphamide
group (12% vs. 4%). Other small trials and several meta-
analyses and systematic reviews have indicated that the
alkylating agents are associated with a higher remission rate,
although the long-term benefits on kidney function could
not be demonstrated.204,236–240
A more recent open-label study204 gave similar results to
the initial trials of Ponticelli. Quality of life, as measured by a
visual analog scale, was significantly better in the treatment
group throughout the follow-up period. The complication
rate was not different in the two groups.
One small open-label RCT (N¼ 29) examined the efficacy
of cyclophosphamide for 12 months plus moderate-dose
steroids in IMN patients considered to be at high risk of
progression (based on urinary IgG and urine b2 micro-
globulin levels) that previously indicated these patients
would have an increase in SCr levels by 425%, and reach
a SCr 41.5mg/dl (4133 mmol/l) or have an increase of
450% from baseline. The study compared an early-start
group (urinary abnormalities at baseline) vs. the group
started only after SCr had risen by 425–50%. They found a
more rapid remission in proteinuria in early-start patients,
but no differences between the two groups in overall
remission rates, SCr levels, average proteinuria, relapse rates,
or adverse events after 6 years.241 This study agrees with
earlier observational studies from the same authors, and
supports an initial conservative treatment approach in IMN
patients. However, toxicity with this specific approach has
been reported to be substantially increased by both prolong-
ing its duration and by selecting patients with impaired
kidney function (SCr 41.5mg/dl [4133 mmol/l]). The
overall evidence for this approach is moderate.241–243 The
adverse effects of alkylating-cytotoxic agents are substantial,
and include gonadal toxicity, bladder carcinoma, bone
marrow hypoplasia, leukemogenesis, and serious opportu-
nistic infections (Table 16). The balance of risk and benefit
may be altered by patient-dependent factors, such as age and
comorbidities. Table 17 lists some of the contraindications to
Table 16 | Risks and benefits of the cyclical corticosteroid/alkylating-agent regimen in IMN
Risks Benefits
Enhanced risk of opportunistic infection
Reactivation of viral hepatitis
Alopecia
Gonadal damage (aspermatogenesis, ovulation failure)
Hemorrhagic cystitis (cyclophosphamide only)
Neoplasia (myelodysplastic syndrome, acute myelogenous leukemia
Transitional cell carcinoma of the bladder, ureter or pelvis
Toxic hepatitis
Prevention of CKD and ESRD
Avoidance of complications of nephrotic syndrome (thrombosis,
accelerated atherogenesis)
Prolongation of life; improved quality of life
CKD, chronic kidney disease; ESRD, end-stage renal disease; MN, membranous nephropathy.
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the use of the cyclical alkylating-agent/steroid regimen.
Cyclophosphamide has a more favorable side-effect profile
compared to chlorambucil. The available evidence does not
suggest a beneficial effect of i.v. cyclophosphamide on the
course of IMN, and its use is not recommended. Based on
limited pharmacokinetic data, the dose of alkylating agents
should be reduced when GFR declines, in order to avoid
bone-marrow toxicity. Azathioprine does not favorably
influence the course of IMN, either alone or with
corticosteroids.244–246
Evidence from studies of immunosuppressed patients
with diseases other than IMN indicates that patients on
corticosteroids should receive prophylaxis for Pneumocystis
jiroveci with trimethoprim-sulfamethoxazole. Those at risk
for osteoporosis (e.g., elderly or postmenopausal females)
should also receive bisphosphonates, unless these are contra-
indicated, such as an eGFRo30ml/min per 1.73m2 (see also
Chapter 1).
Deterioration of kidney function in IMN is usually
slow, and development of advanced CKD most often takes
several years of persistent high-level proteinuria. A rapid
deterioration of kidney function in the absence of massive
proteinuria (e.g., 415 g/d) usually indicates the super-
imposition of another pathologic process, such as acute
bilateral renal-vein thrombosis, a superimposed crescentic
GN, or acute interstitial nephritis. A repeat kidney
biopsy is the most appropriate tool to identify any patho-
logy changes that may require a change in treatment.
In patients with severe proteinuria (410–15 g/d), however,
an acute decline in kidney function (o50% reduction in
GFR) can be seen, possibly as a result of hemodynamic
changes. This usually reverses with remission of the nephrotic
state, and hence does not require a change in the therapeutic
approach.
Prospective controlled studies of the use of immunosup-
pressive agents for treatment of patients with IMN and
impaired renal function (e.g., eGFR 30–60ml/min per
1.73m2) are very limited. The current evidence is insufficient
to make any specific recommendation in this group of
patients. The hematological toxicity of alkylating agents can
be heightened in subjects with impaired renal function, and
the nephrotoxicity of CNI in those with already impaired
renal function remains a concern. These agents should be
used with caution in patients with IMN and chronically
reduced renal function.
RESEARCH RECOMMENDATIONS
K Clinical, pathological, and biological markers are needed
to identify patients who will benefit most from therapy,
and also to avoid unnecessary drug exposure risk to the
rest. There is a lack of evidence to guide ideal dosing to
minimize drug toxicity, especially the gonadal and
bladder toxicity of cyclophosphamide.
K RCTs are needed to compare alkylating agents or CNIs
to MMF, rituximab, or adrenocorticotropic hormone
(ACTH) as initial therapy of IMN with nephrotic
syndrome (with or without impaired renal function at
diagnosis).
K Studies are needed to determine the value of renal
pathology and urinary biomarkers in predicting prog-
nosis and/or treatment responsiveness.
K Serial anti-PLA2R antibodies and urinary biomarkers
(such as urinary IgG, b2-microglobulin) should be
measured in natural history studies, and in all future
treatment trials for IMN, in order to assess their value in
determining spontaneous remission, response to treat-
ment, and prognosis.
7.4: Alternative regimens for the initial therapy of IMN:
CNI therapy
7.4.1: We recommend that cyclosporine or tacroli-
mus be used for a period of at least 6 months
in patients who meet the criteria for initial
therapy (as described in Recommendation
7.2.1), but who choose not to receive the
cyclical corticosteroid/alkylating-agent regi-
men or who have contraindications to this
regimen. (See Table 18 for specific recommen-
dations for dosage during therapy.) (1C)
7.4.2: We suggest that CNIs be discontinued in
patients who do not achieve complete or
partial remission after 6 months of treatment.
(2C)
7.4.3: We suggest that the dosage of CNI be reduced
at intervals of 4–8 weeks to a level of about
50% of the starting dosage, provided that
remission is maintained and no treatment-
limiting CNI-related nephrotoxicity occurs,
and continued for at least 12 months. (2C)
7.4.4: We suggest that CNI blood levels be monitored
regularly during the initial treatment period,
and whenever there is an unexplained rise in
SCr (420%) during therapy. (Not Graded)
(See Table 18 for specific CNI-based regimen
dosage recommendations.)
RATIONALE
There is low- to moderate-quality evidence to support
a recommendation for CNI therapy (cyclosporine or
Table 17 | Contraindications to the use of the cyclical
corticosteroid/alkylating-agent regimen in IMN
Untreated infection (HIV, hepatitis B and C, tuberculosis, fungal infection,
etc.)
Neoplasia (lung, skin [except squamous cell]), breast, colon, etc.
Urinary retention
Inability to comply with monitoring
Pre-existing leukopenia (o4000 leukocytes/mm3)
SCr 43.5mg/dl (4309mmol/l)
HIV, human immunodeficiency virus; MN, membranous nephropathy; SCr, serum
creatinine.
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tacrolimus) as an alternative to cyclical corticosteroid/
alkylating-agent therapy in IMN (Online Suppl Tables
28–31). There is low-quality evidence to suggest that a
minimum of 6 months therapy with CNI should be
employed, which should be continued for at least 6–12
months if there is a beneficial effect on proteinuria, based
on the high relapse rates if therapy is discontinued early.
The suggested dosage regimens for CNIs in IMN are given
in Table 18.
Cyclosporine
Early uncontrolled studies suggested an initial benefit,
but a high relapse rate, with cyclosporine in IMN.247,248 In
a single-blind, randomized controlled study, 51 patients with
steroid-resistant MN were treated with low-dose prednisone
plus cyclosporine and compared to placebo plus predni-
sone.249 Complete and partial remissions in proteinuria were
seen in 69% of the patients, but the relapse rate when
cyclosporine was discontinued was high, approximately 45%
of the end of 1 year. Observational data from the German
Cyclosporine in NS Study Group suggests that prolonging
cyclosporine treatment for 1 year results in higher (34%)
complete remission at 1 year, and more sustained rate of
remissions.144 Current recommendations, for patients who
respond to cyclosporine, are to continue treatment for at least
1 year.182 Prolonged low-dose cyclosporine (B1.5mg/kg/d)
could be considered for long-term maintenance of
patients who achieve a complete or partial remission,
especially in patients at high risk for relapse.250 Regular
monitoring of cyclosporine blood concentration as well as
kidney function is often recommended, according to data
accumulated from experiences in kidney transplantation.
There is no evidence in patients with IMN to indicate
optimal cyclosporine blood levels. Cyclosporine levels usually
regarded as nontoxic are 125–175 ng/ml [104–146 nmol/l]
(C0, trough level) or 400–600 ng/ml [333–500 nmol/l] (C2,
2-hour post-dose level).182 Online Suppl Tables 28–31
summarize studies using cyclosporine.208,247,251–253
There has been only one small RCT using cyclosporine
in patients with high-grade proteinuria and progressive
kidney failure.251 At the time of initiation of treatment, mean
CrCl was 55ml/min, and mean proteinuria 11 g/d. After 12
months of treatment with cyclosporine, there was a
significant reduction in proteinuria, and the rate of loss of
kidney function decreased from 2.4 to 0.7ml/min/mo,
whereas, in those receiving placebo, there was no change:
2.2 to 2.1ml/min/mo (P o0.02). This improvement was
sustained in B50% of the patients for up to 2 years after
cyclosporine was stopped.208,247,251–253
Tacrolimus
In an RCT using tacrolimus monotherapy in IMN, patients
with normal kidney function (n¼ 25) and mean proteinuria
(B8 g per 24 hours) received tacrolimus (0.05mg/kg/d) over
12 months with a 6-month taper, and were compared to
conservatively treated controls (n¼ 23).254 After 18 months,
the probability of remission was 94% in the tacrolimus group
but only 35%, in the control group. Six patients in the
control group and only one in the tacrolimus group reached
the secondary end-point of a 50% increase in SCr.254 Almost
half of the patients relapsed after tacrolimus was withdrawn,
similar to patients treated with cyclosporine. There is only
low-quality evidence to support prolonged use of low-dose
tacrolimus to maintain remission; the safety of this approach
is uncertain.226,227,229,230,233–235,238,240,242,243,255–258
Comparison Studies of CNIs vs. Alkylating Agents
An RCT in IMN patients of Asian ancestry has compared
tacrolimus (n¼ 39) for 6–9 months to oral cyclophos-
phamide (n¼ 34) for 4 months (both groups received
prednisone tapered off over 8 months).259 The results
indicated no difference between treatments in terms of
partial or complete remission of proteinuria (79% vs. 69%),
or adverse events at 12 months of follow-up. Relapses
occurred in approximately 15% of both groups. These
data support the use of tacrolimus, short-term (with or
without concomitant steroids) as an alternative to an oral
alkylating-agent regimen.254 However, the long-term
efficacy of a tacrolimus-based regimen for IMN remains
uncertain.259
Use of CNIs in Patients with Reduced Renal Function
The nephrotoxicity of CNIs can be enhanced in the presence
of pre-existing renal functional impairment. Cyclophospha-
mide-based regimens may be preferred in this situation, but
dose reduction of the alkylating agent is advisable. There is
weak evidence for preferring CNI or alkylating agent–based
regimens in this group of patients. An RCT examining this
controversial area is in progress (ISRCTN99959692). The use
of other agents, including rituximab, MMF, and/or ACTH in
this group of subjects is worthy of further study, but the
evidence is currently insufficient to make any specific
recommendations. The evidence concerning the value of
quantification of the degree of interstitial fibrosis and/or
tubular atrophy in renal biopsy as a guide for the choice of
treatment regimens for IMN is presently insufficient to make
any recommendations.
Table 18 | CNI-based regimens for IMN
Cyclosporine: 3.5–5.0mg/kg/d given orally in two equally divided
doses 12 hours apart, with prednisone 0.15mg/kg/d, for 6 months.
We suggest starting at the low range of the recommended dosage
and gradually increasing, if necessary, to avoid acute nephrotoxicity
(Sandimmunes, Neorals, and generic cyclosporin considered equivalent).
Tacrolimus: 0.05–0.075mg/kg/d given orally in two divided doses
12 hours apart, without prednisone, for 6–12 months. We suggest starting
at the low range of the recommended dosage and gradually increasing,
if necessary, to avoid acute nephrotoxicity.
IMN, idiopathic membranous nephropathy.
Note: Monitoring of blood levels during therapy is discussed in the text.
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RESEARCH RECOMMENDATIONS
K RCTs are needed in IMN to assess the efficacy, safety, and
risks of long-term CNI therapy.
K Studies are needed to determine the value of monitoring
blood levels of CNIs during therapy of IMN.
7.5: Regimens not recommended or suggested for initial
therapy of IMN
7.5.1: We recommend that corticosteroid mono-
therapy not be used for initial therapy of
IMN. (1B)
7.5.2: We suggest that monotherapy with MMF not
be used for initial therapy of IMN. (2C)
BACKGROUND
A number of treatments, other than combined therapy of
corticosteroid/alkylating agents or CNIs, have been tried as
initial therapy in IMN (meeting the criteria outline in
Recommendation 7.2.1). However, none of these have been
shown in appropriately sized RCTs to be consistently effective
and safe, and therefore are not recommended as ‘‘first-line’’
initial therapy in IMN.
RATIONALE
Corticosteroid Monotherapy
There is moderate-quality evidence to recommend not using
corticosteroid monotherapy for inducing remissions or
delaying the onset of progressive CKD in IMN. An early
study reported that a 2- to 3-month course of high-dose,
alternate-day prednisone resulted in a significant reduction
compared to placebo in progression to kidney failure,
although there was no sustained effect on proteinuria.260 A
subsequent RCT in patients with IMN, using an identical
corticosteroid regimen vs. placebo, showed no improvement
during drug exposure, or over a 3-year follow-up in either
proteinuria or kidney function (SCr). An additional RCT
comparing a 6-month course of prednisone given on
alternate days (n¼ 81) to no specific treatment (n¼ 77)
showed no significant benefit of corticosteroid treatment
alone, in either induction of remission or preservation
of kidney function, even after the data were adjusted to
include only patients with proteinuria at entry 43.5 g per
24 hours.261 Nevertheless, retrospective studies conducted in
subjects of Asian (Japanese) ancestry have suggested possible
benefits for steroid monotherapy.262 These analyses could be
confounded by unmeasured variables and failure to subject
patients to an observation period prior to initiation of
therapy. The negative RCTs mentioned included too few
Asian subjects for subanalysis.
MMF (Online Suppl Tables 32–34)
MMF as initial therapy in IMN has not been shown in RCTs
to be consistently effective for inducing remissions or
delaying the onset of progressive CKD. Thirty-two patients
with IMN and impairment of kidney function (SCr
41.5mg/dl [4133 mmol/l]) were treated with oral MMF
1 g twice daily for 12 months, in combination with
corticosteroids, and compared to 32 patients—historical
controls treated for the same duration with oral cyclo-
phosphamide in combination with corticosteroids (cyclo-
phosphamide; 1.5mg/kg/d).263 Cumulative incidences of
remission of proteinuria at 12 months were 66% with
MMF vs. 72% with cyclophosphamide (P¼ 0.3). Adverse
effects occurred at a similar rate in the two groups, but
relapses were very much more common with MMF, and
relapses were noted even while on treatment.263
There have been two small RCTs that have compared
MMF plus steroids to the Ponticelli regimen of an alkylating
agent (cyclophosphamide or chlorambucil) plus steroids.
In one study of 20 low risk-of-progression adults that were
all drug-naı¨ve with nephrotic syndrome due to IMN, the
efficacy of a regimen of MMF plus corticosteroids was
compared to a modified Ponticelli regimen (with chloram-
bucil).264 There was no significant difference in the propor-
tion of patients achieving remission: 64% with MMF, 67%
with the modified Ponticelli regimen. The frequency of
relapses and incidence of infections were similar in both
groups. There was more leucopenia with the modified
Ponticelli regimen, compared to MMF. In the other small
RCT264A 21 drug naı¨ve IMN patients, MMF plus steroids was
compared to the Ponticelli regimen. The complete or partial
response rate was 64% (7/11) in the MMF versus 80% (8/10)
with the alkylating/steroid regimen. In a short follow-up
period no patience relapsed in the MMF group and only one
in the Ponticelli regimen (NS).
By contrast, in a pilot RCT in a low risk-of-progression
adults that were all drug naı¨ve with nephrotic syndrome
due to IMN, the efficacy of a MMF based monotherapy
regimen (no concomittantt steroids) was compared to
conservative therapy alone. This study randomized 36
patients with IMN and nephrotic syndrome to conservative
therapy (RAS blockade, statins, low-salt and low-protein diet,
and diuretics) plus MMF (2 g/d, without concomitant
steroids) (n¼ 19) or conservative therapy alone (n¼ 17)
for 12 months.265 The probability of a complete or partial
remission did not differ between the two groups after
12 months.
Thus, while a regimen of MMF plus steroids might have
comparable efficacy to the standard regimen of cyclical
alkylating agents and steroids, the present evidence is
conflicting, of low quality, and only short-term. The high
frequency of relapses with MMF substantially reduces
enthusiasm regarding this approach to therapy of IMN.263
Monotherapy with MMF appears to be ineffective.265
Rituximab
As yet, there are no RCTs using rituximab for initial therapy
of IMN, although large observational studies have provided
encouraging data. A pilot study used four weekly doses of
rituximab (375mg/m2) in eight nephrotic patients with IMN
and followed them for 1 year.266,267 Proteinuria significantly
decreased at 12 months, and kidney function remained stable
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in all patients. Adverse effects were reported as mild. An
observational study from the same investigators suggested
that rituximab is likely to be most effective in patients with
minimal degrees of tubulointerstitial injury.268
A prospective observational study in 15 patients with IMN
and proteinuria 44 g per 24 hours—despite ACE-I/ARB use
for 43 months and systolic blood pressure o130mmHg—
has been reported.269 At 6 months, patients who remained
with proteinuria 43 g per 24 hours, and in whom total
CD19þ B-cell count was 415 cells/ml, received a second
identical course of rituximab. Baseline proteinuria of 13.0±
5.7 g per 24 hours (range 8.4–23.5) decreased to 9.1±7.4 g,
9.3±7.9 g, 7.2±6.2 g, and 6.0±7.0 g per 24 hours (range
0.2–20) at 3, 6, 9, and 12 months, respectively (mean± SD).
The mean decline in proteinuria from baseline to 12 months
was 6.2±5.1 g/d and was statistically significant (P¼ 0.002).
Rituximab was well-tolerated, and was effective in reducing
proteinuria in some patients with IMN. The complete and
partial remission rate was almost 60%, higher than would
have been expected based on known spontaneous remission
rates.
Another observational study used circulating B-cell counts
to guide dosing, significantly reducing total dose of
rituximab.270 At 1 year, the proportion of patients who
achieved disease remission was identical to that of 24
historical patients who were given a standard rituximab
protocol of four weekly doses of 375mg/m2.
More recently, another prospective observational study in
20 patients with IMN and baseline persistent proteinuria
45.0 g/d received rituximab (375mg/m2 weekly for four
doses), with retreatment at 6 months regardless of protein-
uria response.271 Baseline proteinuria of 11.9 g/d decreased to
4.2 g/d and 2.0 g/d at 12 and 24 months, respectively, while
CrCl increased from 72.4 to 88.4ml/min per 1.73m2 at 24
months. Among 18 patients who completed 24 months of
follow-up, four achieved complete remission, 12 achieved
partial remission (complete plus partial remission of 80%).
One patient relapsed during follow-up. More than 50% of the
patients in this pilot trial had not responded to prior therapy.
No short-term toxicity of rituximab was observed. This study
also reinforced the observation, made with alkylating agent/
corticosteroid therapy that proteinuria declines gradually,
and many months may be required for proteinuria to reach
its nadir.
An RCT is needed to confirm these encouraging results,
but the findings indicate a high probability that rituximab
has beneficial actions on the disease process. The long-term
relapse rate is unknown but in the short term, it appears to be
low.271 Due to the lack of RCTs, no specific recommendations
can be made regarding the use of rituximab for initial therapy
of IMN.
ACTH (Online Suppl Tables 26–27)
One observational study and one small RCT provide
preliminary, low-quality evidence for the use of long-acting
ACTH as initial therapy in IMN.
Depot synthetic ACTH (Synacthens) administered for
1 year in an observational study decreased proteinuria
in patients with IMN.272,273 More recently, a small open-
label pilot RCT compared i.v. methylprednisolone and
oral corticosteroids plus a cytotoxic agent (n¼ 16) vs.
synthetic ACTH (n¼ 16) as initial therapy in IMN,
and found them to be of similar efficacy, at least over
short-term follow-up.274 Side-effects associated with the
use of synthetic ACTH included dizziness, glucose intoler-
ance, diarrhea, and the development of bronze-colored
skin, which resolved after the end of therapy. Larger,
more-powerful RCTs are required before synthetic ACTH
can be recommended for initial therapy of IMN. Prelimi-
nary reports of uncontrolled studies showing a similar effect
of native, intact (porcine) ACTH in a gel formulation have
very recently appeared, but no RCTs have yet been conducted
with this formulation of ACTH. Until broader and more
powerful RCTs are performed, no recommendations can be
made for the use of ACTH (synthetic or intact) for initial
therapy of IMN.
RESEARCH RECOMMENDATIONS
K Larger RCTs with longer follow-up are needed to test
MMF and corticosteroids vs. established regimens as
initial therapy.
K An RCT is needed to compare rituximab to cyclical
corticosteroid/alkylating-agent therapy or CNIs for initial
treatment of IMN with nephrotic syndrome.
K An RCT is needed to compare synthetic or native (intact,
porcine) ACTH in gel form with cyclical corticosteroid/
alkylating-agent therapy or CNIs for initial treatment of
IMN with nephrotic syndrome.
7.6: Treatment of IMN resistant to recommended initial
therapy
7.6.1: We suggest that patients with IMN resistant to
alkylating agent/steroid-based initial therapy
be treated with a CNI. (2C)
7.6.2: We suggest that patients with IMN resistant to
CNI-based initial therapy be treated with an
alkylating agent/steroid-based therapy. (2C)
BACKGROUND
The results of trials using an initial cyclical treatment
alternating steroids and an alkylating agent or an initial
CNI have shown excellent kidney survival and a high rate of
remission, even in the long term.204,233–235,249,254,275 However,
9–28% of patients are treatment-resistant (fail to achieve a
remission) to steroids and alkylating-agent therapy, and
approximately 25% of patients are treatment-resistant to CNI
therapy. Patients who fail to achieve a complete or partial
remission of nephrotic syndrome should be considered for
additional therapy if no contraindication to such treatment
exists. The response to alternative therapeutic strategies in
treatment-resistant disease cannot presently be predicted
with any degree of accuracy. Failure to respond to one
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regimen does not reliably predict a failure to respond to
another regimen.
RATIONALE
Unresponsiveness to initial therapy is observed in 10–30% of
patients following a complete course of treatment. There is
low-quality evidence to suggest that failure to respond to one
regimen does not reliably predict failure to respond to
another regimen.
If there is no remission following cyclical treatment with
an alkylating agent/corticosteroid regimen, an alternative is
to use CNIs. Cyclosporine is the best studied, although
tacrolimus has also been shown to induce a high initial rate
of remission, comparable to the overall response rate
observed with combined steroids and alkylating agents,
particularly after a prolonged administration and associated
with moderate doses of steroids.249
Many treatment-resistant patients also have deteriorating
kidney function. There has been only one small RCT
using cyclosporine in patients with high-grade proteinuria
(410 g/d) and progressive kidney failure (initial CrCl
approximately 55ml/min). It showed a significant reduction
in the rate of loss of kidney function with cyclosporine.251
For those patients who receive a CNI for initial therapy and
show no response after a period of at least 6 months, we
suggest treatment with an alkylating agent–based regimen,
using the same regimen as for initial therapy. However,
adverse effects of treatment may be more frequent in patients
with established or progressing kidney impairment. A
randomized trial examining the relative safety and efficacy
of conservative, alkylating agent or CNI therapy in this group
of subjects with IMN is in progress in the UK (ISRCTN
99959692), the results of which could alter recommendations
in this area.
In patients with kidney impairment,243,251 bone marrow is
more susceptible to the toxic effect of alkylating agents, and
there may also be heightened susceptibility to infections.
Therefore, it is recommended not to exceed daily doses
for chlorambucil of 0.1mg/kg and cyclophosphamide of
1.5mg/kg in patients with SCr42.0mg/dl [4177 mmol/l]276
and to limit the total duration of therapy to o6 months.
A higher incidence of side-effects with this regimen is to
be expected. The use of CNIs in this group of subjects may
also be associated with worsening renal function due to
nephrotoxicity.
The roles of MMF, rituximab, or ACTH in patients
resistant to both alkylating agent–based and CNI-based
regimens remain undefined; there have been no
RCTs.111,205,263,265,272,274,277
Additional causative factors should be considered when
there is deteriorating renal function in IMN. Rapidly
progressive renal failure may occur from an acute hypersen-
sitivity interstitial nephritis in IMN patients receiving
diuretics, antibiotics, or nonsteroidal anti-inflammatory
drugs. A superimposed crescentic GN associated with anti-
GBM antibodies or ANCA can also rarely develop in those
patients with high-grade proteinuria.278,279 Kidney biopsy is
often necessary to confirm the diagnosis, and complete
recovery of kidney function may follow a course of high-dose
oral prednisone in those with acute hypersensitivity inter-
stitial nephritis or intensive immunosuppression in those
with crescentic disease (see Chapters 13 and 14).
Finally, pulses of i.v. methylprednisolone as mono-
therapy should not be used for treatment of resistant
disease, unless the steady evolution of IMN is interrupted
by a rapidly progressive course, and an extracapillary
(crescentic) GN superimposed on IMN is shown by kidney
biopsy.
RESEARCH RECOMMENDATIONS
K RCTs are needed to assess risks and benefits of rituximab,
MMF, and ACTH in the treatment of IMN patients
resistant to first-line therapy.
K RCTs are needed to assess risks and benefits of the cyclical
alkylating agent/corticosteroid regimen or with a CNI
regimen in IMN patients with impaired or deteriorating
kidney function.
7.7: Treatment for relapses of nephrotic syndrome in adults
with IMN
7.7.1: We suggest that relapses of nephrotic syn-
drome in IMN be treated by reinstitution of
the same therapy that resulted in the initial
remission. (2D)
7.7.2: We suggest that, if a 6-month cyclical corti-
costeroid/alkylating-agent regimen was used
for initial therapy (see Recommendation
7.3.1), the regimen be repeated only once for
treatment of a relapse. (2B)
BACKGROUND
Clinical trials using cyclical treatment of alternating steroids
and alkylating agents or CNIs in IMN have shown
excellent kidney survival in those subjects with complete
or partial remission, even in the long term. How-
ever, relapses of nephrotic syndrome occur in 25–30% of
patients within 5 years of discontinuation of therapy
with alkylating agents, and 40–50% of patients within
1 year of discontinuation of CNIs. For those patients who
show a complete or partial remission and then a relapse of
nephrotic syndrome, a second course of treatment can be
given.280
RATIONALE
There is very low–quality evidence to suggest that responses
to re-treatment of a relapse are similar to those observed after
the first treatment.
There is moderate-quality evidence to suggest that there
are significant risks of neoplasia induction, opportunistic
infections, and gonadal damage when alkylating agents are
used for an extended period.
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If there is a relapse of nephrotic syndrome in IMN
following remission, reintroduction of a corticosteroid/
alkylating-agent regimen or CNIs will often, but not
uniformly, induce another remission.
Most data on repeated courses of immunosuppressive
therapy relate to patients in whom relapses occurred after a
partial remission, and with normal kidney function.281,282
There are no RCTs to guide therapy for patients with IMN
who relapse after a first course of therapy and have kidney
impairment.283
Cancer induction is a major concern when alkylating
agents are used for an extended period. Cumulative doses
of more than 36 g of cyclophosphamide (equivalent to
100mg daily for 1 year) were associated with a 9.5-fold
increased risk of bladder cancer, in patients with Wegener
granulomatosis. Extended courses have also been associated
with an increased risk of lymphoproliferative, myelodysplas-
tic, and leukemic disorders.284 Because of this, repeated
courses (more than two) of cyclical alkylating-agent therapy
are not advised.
Mild relapses (redevelopment of subnephrotic proteinuria
after a complete remission) do not require any specific
treatment, and should be managed conservatively. Blood
pressure should be kept o125/75mmHg and an ACE-I
or ARB should be used as the first line of treatment (see
Chapter 1).
Other agents such as MMF, rituximab, or ACTH might be
considered for treatment of relapses in IMN. There is some
observational evidence that rituximab may be beneficial in
patients relapsing whenever the dose of CNI is reduced (CNI
dependency),285 but the evidence is currently insufficient to
make any specific recommendations.
RESEARCH RECOMMENDATION
K RCTs are needed to examine the efficacy and safety of
MMF, rituximab, or ACTH in relapsing patients with
IMN.
7.8: Treatment of IMN in children
7.8.1: We suggest that treatment of IMN in children
follows the recommendations for treatment of
IMN in adults. (2C) (See Recommendations
7.2.1 and 7.3.1.)
7.8.2: We suggest that no more than one course
of the cyclical corticosteroid/alkylating-agent
regimen be given in children. (2D)
BACKGROUND
IMN in children is uncommon, and usually presents as
nephrotic syndrome or asymptomatic proteinuria. IMN
contributes less than 5% of cases of nephrotic syndrome in
children.286,287 Most cases (475%) of MN in children are
secondary to chronic viral infections (e.g., hepatitis B),
autoimmune diseases (SLE, thyroiditis), or drugs.
RATIONALE
There is low-quality evidence to suggest children with IMN
should be treated with the same regimens as adults, with
appropriate dosage modification.
Most knowledge of the natural history of IMN in children,
treatment options, and long-term outcome is derived from
small, uncontrolled observational studies288 that suggest a
relatively high spontaneous remission rate, and a low incidence
of ESRD. Children with IMN will not usually require more
than conservative therapy, unless they are severely sympto-
matic, as they seem to have a higher spontaneous remission
rate than adults. For children with severe symptomatic disease,
the same drug combinations used in adults are suggested, with
appropriate dosage adjustments.289 Most of these protocols
use chlorambucil 0.15–0.2mg/kg/d or cyclophosphamide
2mg/kg/d for 8–12 weeks, with alternate-day prednisone.
The risk for gonadal toxicity with chlorambucil and cyclo-
phosphamide is greater in boys than in girls, and is related
to both the duration and total dose of treatment.290 The
cumulative dose of cyclophosphamide should not exceed
200mg/kg in order to avoid gonadal toxicity.
There are no data on the use of CNIs in children with
IMN; the use of CNIs is based only on the evidence from
adults RCTs. MMF, rituximab, or ACTH has not been studied
in children (see also Table 19).
RESEARCH RECOMMENDATION
K The absence of RCTs of treatment of IMN in children
makes treatment recommendations and suggestions
moot. RCTs are needed to compare the use of alkylating
agents and CNIs for initial therapy of IMN children with
nephrotic syndrome.
7.9: Prophylactic anticoagulants in IMN
7.9.1: We suggest that patients with IMN and
nephrotic syndrome, with marked reduction
in serum albumin (o2.5 g/dl [o25 g/l]) and
additional risks for thrombosis, be considered
for prophylactic anticoagulant therapy, using
oral warfarin. (2C)
BACKGROUND
IMN seems to constitute a special hazard for venous
thromboembolism and spontaneous vascular thrombosis
(such as deep venous thrombosis or pulmonary artery
embolism/thrombosis), even more so than other causes of
nephrotic syndrome (see also Chapter 1).301–303 This may also
apply to other types of primary GN associated with severe
nephrotic syndrome; the evidence base, however, is lacking.
There have been no RCTs of prophylactic anticoagulation in
IMN with nephrotic syndrome.301–303
RATIONALE
There is very low–quality evidence to suggest the use of
prophylactic anticoagulation with warfarin in patients with
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IMN and severe nephrotic syndrome. However, based on
Markov modeling of anticipated benefits and risks derived
from observational studies, prophylactic anticoagulation
might be considered when the serum albumin concentration
is o2.0–2.5 g/dl (o20–25 g/l) with one or more of the
following: proteinuria 410 g/d; BMI 435 kg/m2; prior
history of thromboembolism; family history of thrombo-
embolism with documented genetic predisposition; NYHA
class III or IV congestive heart failure; recent abdominal
or orthopedic surgery; prolonged immobilization.301–303
Treatment with warfarin should always be preceded by a
short period of treatment with heparin (fractionated or
unfractionated) in sufficient dosage to obtain prolongation of
the clotting time. Dosage adjustments for fractionated
heparin may be required if kidney function is impaired.
Due to insufficient experience with the use of newer oral or
parenteral anticoagulants in nephrotic syndrome, no recom-
mendations can be made regarding their use for prophylaxis
of thrombosis. The duration of prophylactic anticoagulation
needed for optimal benefit compared to risk is not known,
but it seems reasonable to continue therapy for as long as the
patient remains nephrotic with a serum albumin o3.0 g/dl
(o30 g/l).
RESEARCH RECOMMENDATION
K An RCT is needed of prophylactic warfarin in patients
with nephrotic syndrome with/without additional risk for
thromboembolism in IMN patients.
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Table 19 | Pediatric MN studies
Author N NS Steroids Other immunosuppression Remission
Persistent
disease CRI ESRD
Habib et al.291 50 72% 54% 44% (mechlorethamine and chlorambucil) 52% 38% ? 10%
Olbing et al.292 9 78% 89% 22% cyclophosphamide, 11% azathioprine 33% 33% 33% 0%
Chan and Tsao293 10 80% 100% None 50% 40% 0% 10%
Trainin et al.294 14 79% 79% 57% ‘‘cytotoxics’’ 43% 29% 7% 21%
Latham et al.295 14 100% p93% p93%: cyclophosphamide 29% 50% 7% 14%
Ramirez et al.296 22 82% 50% 5% azathioprine + cyclophosphamide, 5% chlorambucil 27% 45% 23% 5%
Tsukahara et al.297 12 25% 42% 17% cyclophosphamide 67% 33% 0% 0%
Lee et al.298 19 58% 84% 16% cyclosporine 68% 16% 5% 11%
Chen et al.299 13 38% 77% 38% CNI, 23% azathioprine, or MMF ? 61% 23% 0%
Valentini et al.300 12 75% 83% 58% cyclophosphamide 75% 17% 8% 0%
CRI, chronic renal insufficiency; ESRD, end-stage renal disease; MN, membranous nephropathy; MMF, mycophenolate mofetil.
With kind permission from Springer Science+Business Media: Pediatr Nephrol. Membranous nephropathy in children: clinical presentation and therapeutic approach. 2010;
25:1419–1428. Menon S, Valentini RP288; accessed http://www.springerlink.com/content/2222k3x102551528/fulltext.pdf.
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